Skip to main content

Profound Medical Corp(PRN-T)
TSX

Today's Change
Real-Time Last Update
Day Low8.92
Day High9.71
Open:9.04
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
Stocks in play: Profound Medical Corp.
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
Upcoming Meeting Dates - March 23, 2026
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
Profound Medical Announces Upcoming Investor Events
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal
Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case
Profound Medical Corp. Announces Closing of Private Placement
Profound Medical Corp. Announces Upsize of Private Placement
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
Profound Medical Reports Strong Third Quarter 2025 Financial Results
Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
Profound Medical to Participate in the Stifel 2025 Healthcare Conference
Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

Profile

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.